Previous 10 | Next 10 |
2023-12-19 10:11:12 ET Penny Stocks and Preparing for 2024 As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023’s ups and downs; maybe not. For those interested in penny stocks, the high-risk but potentially...
2023-12-12 11:12:22 ET More on Delcath Systems Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects Seeking Alpha’s Quant Rating on Delcath Systems Historical earnings data for Delcath Systems For further details see: Del...
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research PR Newswire Retrospective Analysis of Changes in Patients with Metastatic Uveal Melanoma treated with Chemosat Hepatic Delivery Sy...
2023-11-21 15:01:47 ET Is the stock market open on Thanksgiving? No, but that doesn’t mean the shortened holiday week won’t be packed with stock market moving catalysts. And before you ask, yes, the stock market is open on Black Friday for a half day, so there’s plenty ...
2023-11-17 18:40:33 ET Summary Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by ...
2023-11-13 22:07:06 ET Delcath Systems Inc. (DCTH) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - Gene...
2023-11-13 16:17:18 ET More on Delcath Systems Delcath Systems: Prepare For Substantial Dilution Post-FDA Approval For The Hepzato Kit Delcath Systems Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Delcath Systems Historical earnings data for...
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update PR Newswire NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Delcath Systems Inc. (DCTH) is expected to report $-0.5 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems Inc. Company Name:
DCTH Stock Symbol:
OTCMKTS Market:
Delcath Systems Reports First Quarter 2024 Results and Business Highlights PR Newswire Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y. , May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an ...
2024-05-13 18:15:04 ET Stephens analyst issues OVERWEIGHT recommendation for DCTH on May 13, 2024 04:20PM ET. DCTH was trading at $5.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold rec...
Delcath Systems to Host First Quarter 2024 Earnings Call PR Newswire QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the live...